Status:
WITHDRAWN
The Zambia Ivermectin Trial for the Treatment and Prevention of COVID-19
Lead Sponsor:
Centre for Infectious Disease Research in Zambia
Collaborating Sponsors:
Ministry of Health, Zambia
University of Zambia
Conditions:
SARS-CoV-2
Ivermectin
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The study aims to test whether Ivermectin would decrease mortality and reduces chances of getting infected with corona virus, improve management of clinical symptoms and reduce length of stay in ICU a...
Detailed Description
With the onset of global pandemic of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the sharp rise in infection and mortality rates, efficient management of the current medical e...
Eligibility Criteria
Inclusion
- Individuals diagnosed positive for SARS-CoV-2 by real-time reverse transcription PCR (rRT-PCR with presence of a fever, cough, and/or sore throat.
Exclusion
- Patients will be excluded if they report to be allergic to ivermectin or if there is potential for a drug-drug interaction with ivermectin;
- Have chronic illnesses (e.g., ischemic heart disease, heart failure, documented cardiomyopathy, chronic kidney disease, chronic liver disease);
- Have received ivermectin in the last 7 days; are pregnant or lactating;
- Or have participated in any other clinical trial within the last month.
Key Trial Info
Start Date :
October 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04891250
Start Date
October 1 2021
End Date
June 1 2022
Last Update
February 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Zambia
Lusaka, Zambia, 10101